UnitedHealth Forecast, price target & analysts
UnitedHealth Target price 2025 - Analyst rating & recommendation
UnitedHealth Classifications & Recommendation:
UnitedHealth Price Target
| Target Price | $565.17 |
| Price | $424.25 |
| Potential | 33.22% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target UnitedHealth 2026 . The average UnitedHealth target price is $565.17. This is 33.22% higher than the current stock price. The highest price target is $677.00 59.58% , the lowest is $490.00 15.50% . | |
| A rating was issued by 30 analysts: 27 Analysts recommend UnitedHealth to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2026 of 33.22% . Most analysts recommend the UnitedHealth stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
21 Analysts have issued a sales forecast UnitedHealth 2025 . The average UnitedHealth sales estimate is $451b . This is 10.05% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $458b 11.76% , the lowest is $444b 8.37% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $400b | 8.83% |
|---|---|---|
| 2025 | $451b | 12.74% |
| 2026 | $486b | 7.75% |
| 2027 | $522b | 7.30% |
| 2028 | $569b | 9.03% |
| 2029 | $613b | 7.75% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
14 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is $24.88 . This is 4.01% higher than earnings per share in the financial year 2024. The highest EPS forecast is $26.20 9.53% , the lowest is $24.60 2.84% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $15.51 | 35.00% |
|---|---|---|
| 2025 | $24.88 | 60.41% |
| 2026 | $29.00 | 16.56% |
| 2027 | $33.31 | 14.86% |
| 2028 | $39.06 | 17.26% |
| 2029 | $44.40 | 13.67% |
P/E ratio
| Current | 17.73 | 42.08% |
|---|---|---|
| 2025 | 17.05 | 3.84% |
| 2026 | 14.63 | 14.19% |
| 2027 | 12.74 | 12.92% |
| 2028 | 10.86 | 14.76% |
| 2029 | 9.55 | 12.06% |
Based on analysts' sales estimates for 2025, the UnitedHealth stock is valued at an EV/Sales of 0.97 and an P/S ratio of 0.86 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.07 | 21.32% |
|---|---|---|
| 2025 | 0.97 | 9.00% |
| 2026 | 0.90 | 7.20% |
| 2027 | 0.84 | 6.80% |
| 2028 | 0.77 | 8.29% |
| 2029 | 0.72 | 7.19% |
P/S ratio
| Current | 0.95 | 22.27% |
|---|---|---|
| 2025 | 0.86 | 9.14% |
| 2026 | 0.80 | 7.19% |
| 2027 | 0.74 | 6.80% |
| 2028 | 0.68 | 8.28% |
| 2029 | 0.63 | 7.20% |
Current UnitedHealth Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
| HSBC |
Buy
➜
Hold
|
Downgrade | Apr 22 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Apr 22 2025 |
| Argus Research |
Buy
➜
Hold
|
Downgrade | Apr 21 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 21 2025 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Apr 24 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
|
Downgrade
HSBC:
Buy
➜
Hold
|
Apr 22 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Apr 22 2025 |
|
Downgrade
Argus Research:
Buy
➜
Hold
|
Apr 21 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 21 2025 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Apr 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
